Patents by Inventor Wilhelmus T. Goedemans

Wilhelmus T. Goedemans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5395946
    Abstract: The invention related to a method of preparing a protein or a proteinaceous material labelled with a metalradionuclide and intended for diagnostic or therapeutic application, by reacting a protein or a proteinaceous material with an agent for coupling the radionuclide to the protein or the proteinaceous material, a protein conjugate being formed, and by then complexing the radionuclide with the conjugate thus formed to a radionuclide complex.
    Type: Grant
    Filed: August 7, 1990
    Date of Patent: March 7, 1995
    Inventors: Wilhelmus T. Goedemans, Karel J. Panek
  • Patent number: 5384113
    Abstract: Gentisic acid and its derivatives substantially inhibit peptide autoradiolysis. Gentisic acid or its derivatives may also be used in combination with other stabilizers such as inositol and ascorbic acid to inhibit autoradiolysis of radiolabeled peptides.
    Type: Grant
    Filed: October 13, 1993
    Date of Patent: January 24, 1995
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Edward A. Deutsch, Wilhelmus T. Goedemans, Martinus T. Maria de Jong, Kathleen M. Miller, James W. Brodack
  • Patent number: 4705678
    Abstract: The invention relates to a sterile aqueous solution for radioassaying a radioactive indium compound, which solution is entirely or substantially free from organic solvent, has a pH from 4 to 9, comprises a radioactive indium tropolonate or pyrithionate and has been subjected to a thermal sterilization.The invention also relates to the radioactive labelling of blood cells by treating a suspension of the blood cells with a sterile solution of a radioactive indium compound, in which either (a) a carbon-dioxide-generating substance is previously incorporated in the solution, or (b) a substance which under the labelling conditions generates carbon dioxide is added to the cell suspension, or carbon dioxide is passed through the cell suspension prior to or during the treatment.The invention furthermore relates to a kit for the radioactive labelling of blood cells.
    Type: Grant
    Filed: June 29, 1984
    Date of Patent: November 10, 1987
    Assignee: Mallinckrodt, Inc.
    Inventor: Wilhelmus T. Goedemans
  • Patent number: 4360509
    Abstract: There is disclosed an in vivo radioassay process in which a radioactive chelate of indium and an 8-hydroxyquinoline is introduced into a warmblooded animal having an inflammatory reaction in an area in which the chelate would not accumulate to the same extent if the inflammation were not present. The chelate gathers in the inflamed area, for instance, in a body abscess, or other injury, and its location is determined by radio surveying the body by an external imaging technique.
    Type: Grant
    Filed: December 19, 1979
    Date of Patent: November 23, 1982
    Assignee: Byk-Mallinckrodt CIL B.V.
    Inventor: Wilhelmus T. Goedemans
  • Patent number: 4348375
    Abstract: There are disclosed aqueous, radioassaying solutions of a chelate of radioactive indium and an 8-hydroxyquinoline, having an essential absence of an organic solvent, e.g., alcohol or chloroform. The solutions are useful in radioassaying warmblooded animals.
    Type: Grant
    Filed: December 31, 1979
    Date of Patent: September 7, 1982
    Assignee: Byk-Mallinckrodt CIL B.V.
    Inventor: Wilhelmus T. Goedemans
  • Patent number: 4271141
    Abstract: The present invention provides an improved method for determining the thyroid function by means of an in vitro test using blood serum. Such a method involves an improvement of the procedure whereby (a) a patient's blood serum sample is mixed with a solution containing radioactive thyroxine and with a compound that liberates thyroxine from thyroxine-binding globulin; (b) the test mixture is buffered to achieve proper conditions for carrying out a thyroxine-binding immunoreaction; (c) an antiserum is added to provide antibodies which bind a portion of the thyroxine present by means of such a thyroxine-binding immunoreaction; (d) unbound thyroxine is thereafter separated from the antibody-bound thyroxine; and (e) the relative quantities of bound and unbound thyroxine are then determined by measurement of radioactivity.
    Type: Grant
    Filed: December 11, 1978
    Date of Patent: June 2, 1981
    Assignee: Byk-Mallinckrodt CIL B.V.
    Inventor: Wilhelmus T. Goedemans